Home Cart 0 Sign in  
X

[ CAS No. 10341-26-1 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
3d Animation Molecule Structure of 10341-26-1
Chemical Structure| 10341-26-1
Chemical Structure| 10341-26-1
Structure of 10341-26-1 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 10341-26-1 ]

Related Doc. of [ 10341-26-1 ]

Alternatived Products of [ 10341-26-1 ]

Product Details of [ 10341-26-1 ]

CAS No. :10341-26-1 MDL No. :MFCD02683091
Formula : C5H9NO2 Boiling Point : -
Linear Structure Formula :- InChI Key :OXDIYMHNQAWSCL-UHFFFAOYSA-N
M.W : 115.13 Pubchem ID :7023020
Synonyms :

Calculated chemistry of [ 10341-26-1 ]

Physicochemical Properties

Num. heavy atoms : 8
Num. arom. heavy atoms : 0
Fraction Csp3 : 0.8
Num. rotatable bonds : 0
Num. H-bond acceptors : 2.0
Num. H-bond donors : 1.0
Molar Refractivity : 32.04
TPSA : 38.33 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : No
P-gp substrate : No
CYP1A2 inhibitor : No
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -7.64 cm/s

Lipophilicity

Log Po/w (iLOGP) : 1.17
Log Po/w (XLOGP3) : -0.9
Log Po/w (WLOGP) : -0.86
Log Po/w (MLOGP) : -0.78
Log Po/w (SILICOS-IT) : 1.02
Consensus Log Po/w : -0.07

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 1.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : 0.01
Solubility : 119.0 mg/ml ; 1.03 mol/l
Class : Highly soluble
Log S (Ali) : 0.58
Solubility : 436.0 mg/ml ; 3.78 mol/l
Class : Highly soluble
Log S (SILICOS-IT) : -0.89
Solubility : 14.7 mg/ml ; 0.128 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 0.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 1.6

Safety of [ 10341-26-1 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P305+P351+P338 UN#:N/A
Hazard Statements:H315-H319-H335 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 10341-26-1 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 10341-26-1 ]
  • Downstream synthetic route of [ 10341-26-1 ]

[ 10341-26-1 ] Synthesis Path-Upstream   1~5

  • 1
  • [ 61128-73-2 ]
  • [ 10341-26-1 ]
YieldReaction ConditionsOperation in experiment
85% With 2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphinane-2,4,6-trioxide In tetrahydrofuran; ethyl acetate at 70℃; Inert atmosphere To a solution of ketoxime (0.01 mol) in THF (10 mL) was added T3P (15 mol percent, 50percent soln in EtOAc) and the resulting reaction mixture was stirred at reflux for 1-4 h under nitrogen atmosphere. When the reaction was completed as confirmed by TLC, the solvent was removed under vacuum and the residue was diluted with water (20 mL). The product was extracted with ethyl acetate (2 .x. 20 mL) and the combined organic phase was washed with saturated NaHCO3 solution (1 .x. 10 mL) and brine. The organic phase was dried over anhydrous Na2SO4. The solvent was removed under reduced pressure to afford the desired amides in good purity.
40%
Stage #1: With benzenesulfonyl chloride In acetone at 0℃;
Stage #2: With sodium hydroxide In acetone at 20℃;
Step 2Dihydro-2H-pyran-4(3H)-one oxime [105] (1 g, 8.7 mmol) was dissolved in acetone (20 ml) in a dry two neck round bottom flask. The reaction mixture was cooled to 0 °C followed by addition of benzene sulfonyl chloride[ 106] (9.6 mmol) and stirred for 15 min; after which was added dropwise 2.5 N NaOH (384 mg, 9.6 mmol). The reaction mixture was stirred at RT overnight. TLC showed complete consumption of starting material. The excess of solvent was removed under reduced pressure on rotary evaporator to yield a white solid. The product was purified by column chromatography over 100-200 silica mesh using 5percent MeOH: DCM as eluent to gave 1,4- oxazepan-5-one [107] as a light yellow solid (0.4 g, 40percent).ESIMS: 1 16.2 (M+ + 1)
Reference: [1] Tetrahedron Letters, 2011, vol. 52, # 10, p. 1074 - 1077
[2] Patent: WO2012/101654, 2012, A2, . Location in patent: Page/Page column 67-68
[3] Zhurnal Obshchei Khimii, 1955, vol. 25, p. 133,135; engl. Ausg. S. 119, 121
[4] Zhurnal Obshchei Khimii, 1955, vol. 25, p. 133,135; engl. Ausg. S. 119, 121
[5] Bioorganic and Medicinal Chemistry Letters, 2001, vol. 11, # 19, p. 2651 - 2653
[6] Patent: US6372733, 2002, B1, . Location in patent: Example 3
  • 2
  • [ 29943-42-8 ]
  • [ 10341-26-1 ]
YieldReaction ConditionsOperation in experiment
47.4% With hydrogenchloride; sodium azide In water at 0 - 20℃; for 17 h; 1)
1,4-Oxazepan-5-one
Under cooling on ice, sodium azide (17.8 g) was added to a solution of tetrahydro-4H-pyran-4-one (9.80 g) in concentrated hydrochloric acid (50 mL) over 40 minutes, and the mixture was stirred for 30 minutes and then at room temperature for 16 hours.
Under cooling on ice, sodium carbonate was added to the reaction mixture to make the pH condition to 8 to 9, and chloroform was added thereto for partitioning the mixture.
The organic layer was washed with saturated brine and then dried over magnesium sulfate anhydrate.
After a filtration step, the solvent was removed under reduced pressure, to thereby give [1,4]oxazepan-5-one as a solid product (5.34 g, 47.4percent).
1H-NMR (300MHz, CDCl3) δ:2.70-2.74 (2H, m), 3.32-3.37(2H,m), 3.75-3.83(4H,m), 6.31 (1H, br s).
MS(FAB)m/z:116(M+H)+.
34.8% at 0 - 20℃; for 8 h; Example 83. Synthesis of 2-(4-(3-(l,4-oxazepan-4-yl)-lH-pyrazol-l-yl)-5-oxo-6,7- ihydro-5H-pyrrolo[3,4-b]pyridin-2-yl)-3-fluorobenzonitrile, 1-83 Synthesis of compound 83.2. To a cooled mixture of 83.1 (10.0 g, 99 mmol, 1.0 eq) in concentrated HC1 (52 mL) at 0 °Cwas added sodium azide (11 g, 167 mmol, 1.69 eq) portion wise. Reaction mixture was stirred at room temperature for 8 h. Upon completion of the reaction, reaction mixture was transferred into water, basified to pH=9.0 by sodium carbonate and extracted with DCM. Combined organic layers were washed with brine solution, dried over sodium sulphate and concentrated under reduced pressure to obtained crude. 83.2 . (4.0 g, 34.8percent). MS(ES): m/z 116.3 [M+H]+.
48% With sodium carbonate In hydrogenchloride; water Preparation 33
1,4-Oxazepane
To a stirred solution of tetrahydro4H-pyran-4-one (4.19 mL) in conc. HCl (23 mL) cooled to 0° C. is added portion-wise sodium azide (4.42 mL).
After addition was complete, the reaction is stirred at room temperature for 4 h.
Solid sodium carbonate is added portion-wise until the solution was slightly alkaline (pH=9).
Water is added during addition of sodium carbonate to dissolve the salt.
The alkaline solution is diluted with CHCl3 (125 mL) and the phases are separated.
The aqueous layer are extracted with CHCl3 (2*75 mL).
The combined organic layers are dried (Na2SO4), filtered, and concentrated to afford 2.5 g (48percent) of 1,4-oxazepan-5-one as an orange-brown residue. 1H NMR (300 MHz, CDCl3) δ6.66, 3.80, 3.35, 2.72.
Reference: [1] Patent: EP1621537, 2006, A1, . Location in patent: Page/Page column 39
[2] Patent: WO2017/40757, 2017, A1, . Location in patent: Paragraph 00395-00396
[3] Patent: US6248739, 2001, B1,
[4] Tetrahedron Letters, 2011, vol. 52, # 10, p. 1074 - 1077
[5] Patent: WO2012/101654, 2012, A2,
  • 3
  • [ 61108-59-6 ]
  • [ 10341-26-1 ]
Reference: [1] Bioorganic and Medicinal Chemistry Letters, 2004, vol. 14, # 23, p. 5907 - 5911
  • 4
  • [ 61128-73-2 ]
  • [ 73920-62-4 ]
  • [ 10341-26-1 ]
Reference: [1] Patent: US6043358, 2000, A,
  • 5
  • [ 29943-42-8 ]
  • [ 10341-26-1 ]
Reference: [1] Journal of Organic Chemistry, 2016, vol. 81, # 4, p. 1593 - 1609
Same Skeleton Products
Historical Records

Related Functional Groups of
[ 10341-26-1 ]

Amides

Chemical Structure| 37714-64-0

[ 37714-64-0 ]

Ethyl 3-morpholino-3-oxopropanoate

Similarity: 0.73

Chemical Structure| 142-78-9

[ 142-78-9 ]

N-(2-Hydroxyethyl)dodecanamide

Similarity: 0.69

Chemical Structure| 544-31-0

[ 544-31-0 ]

Palmitoylethanolamide

Similarity: 0.69

Chemical Structure| 127958-63-8

[ 127958-63-8 ]

6-Methylmorpholin-3-one

Similarity: 0.69

Chemical Structure| 68108-18-9

[ 68108-18-9 ]

(S)-4-Hydroxypyrrolidine-2-one

Similarity: 0.69

Related Parent Nucleus of
[ 10341-26-1 ]

Aliphatic Heterocycles

Chemical Structure| 37714-64-0

[ 37714-64-0 ]

Ethyl 3-morpholino-3-oxopropanoate

Similarity: 0.73

Chemical Structure| 25747-41-5

[ 25747-41-5 ]

4-Hydroxy-2-pyrrolidone

Similarity: 0.69

Chemical Structure| 127958-63-8

[ 127958-63-8 ]

6-Methylmorpholin-3-one

Similarity: 0.69

Chemical Structure| 68108-18-9

[ 68108-18-9 ]

(S)-4-Hydroxypyrrolidine-2-one

Similarity: 0.69

Chemical Structure| 22677-21-0

[ 22677-21-0 ]

(R)-4-Hydroxypyrrolidin-2-one

Similarity: 0.69

Other Aliphatic Heterocycles

Chemical Structure| 178312-62-4

[ 178312-62-4 ]

1,4-Oxazepane hydrochloride

Similarity: 0.67

Chemical Structure| 1292369-55-1

[ 1292369-55-1 ]

6-Hydroxyazepan-2-one

Similarity: 0.63

Chemical Structure| 673-66-5

[ 673-66-5 ]

Azocan-2-one

Similarity: 0.58

Chemical Structure| 105-60-2

[ 105-60-2 ]

Azepan-2-one

Similarity: 0.58

Chemical Structure| 1354952-28-5

[ 1354952-28-5 ]

2-Oxa-5-azabicyclo[4.1.0]heptane hydrochloride

Similarity: 0.58